fashion -WSS

fashion

author：focus 2025-09-30 18:16:58 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare reduced heart disease by changing how it pays doctors

hotspot

focus

WSS

Researchers explore possible ties between long Covid, menopause

Trump surgeon general acknowledges mistakes during Covid

How climate

FDA struggles to regulate food additives, sometimes for decades

NIH confirmation hearing shows politicization of research

FDA warns J&J's Abiomed: We will regulate your software

hotspot

fashion

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

FDA warns J&J's Abiomed: We will regulate your software

As demand for Covid shots wanes, Moderna seeks its next success

Ethical issues complicate the benefits of medical crowdfunding

Medicare details structure of new drug price negotiation program

HHS leader on health, climate change and biopharma emissions

In Memoriam: Notable people who died in 2023

First Opinion Podcast: Long Covid needs a new approach

Trump demands the U.S. pay no more for drugs than other countries … again

The EU Joint Clinical Assessment needs to live up to its promise

leisure time

First Opinion Podcast: Long Covid needs a new approach

Pharmacists can make shortage drugs, but at what cost?

Studies point to risks of excluding people with obesity from drug trials

Stem cell treatment guidelines are released by FDA

Covid hospitalizations on the rise, Humana says

NIH confirmation hearing shows politicization of research

hotspot

focus

focus

knowledge